

MMCI metrics

Sponsor summary on site performance in FIH trial

- FIH clinical trial of novel ADC, as monotherapy as well as in combination of established SoC
 - Selected GI indication of high unmet medical need
 - 6 sites in CZ + WE EU countries, 2 sites in US
-
- APR 2024

FIH trial

- Operational

- European CTA submission (regulatory + ECs) on 13 Jan 2022
- **1st patient enrolled 31 Mar 2022 (i.e. in approx. 2.5 month of submission)**
- 100% PI attendance on dose escalation meetings

- Patient enrollment

- **Top recruiter with enrolled 9 patients out of 33 in total (at 8 sites in EU + US)**

- Data performance

- **Data entry on average in 1 day of the visit date**
- **Overall query rate / page = 1.65 (TOP site in trial)**
- **TAT for query response = 1.14 day (TOP site in trial)**

- Compliance

- **Successful GCP inspection by local regulatory authority without any critical observation**